Interim CEO of DexCom Jacob Leach Buys 6.6% More Shares

DexCom, Inc. (NASDAQ:DXCM) shareholders (or potential shareholders) will be happy to see that the Interim CEO, Jacob Leach, recently bought a whopping US$1.0m worth of stock, at a price of US$55.04. While that only increased their holding size by 6.6%, it is still a big swing by our standards.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

DexCom Insider Transactions Over The Last Year

The Executive Chairman & CEO (Leave of Absence), Kevin Sayer, made the biggest insider sale in the last 12 months. That single transaction was for US$2.9m worth of shares at a price of US$86.91 each. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The good news is that this large sale was at well above current price of US$59.72. So it is hard to draw any strong conclusion from it.

Over the last year we saw more insider selling of DexCom shares, than buying. The chart below shows insider transactions (by companies and individuals) over the last year. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

View our latest analysis for DexCom

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

Does DexCom Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. We usually like to see fairly high levels of insider ownership. It appears that DexCom insiders own 0.3% of the company, worth about US$74m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About DexCom Insiders?

It's certainly positive to see the recent insider purchase. On the other hand the transaction history, over the last year, isn't so positive. We don't take much heart from transactions by DexCom insiders over the last year. But they own a reasonable amount of the company, and there was some buying recently. In short they are likely aligned with shareholders. Of course, the future is what matters most. So if you are interested in DexCom, you should check out this free report on analyst forecasts for the company.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.